论文部分内容阅读
本实验应用小鼠可移植性自发乳腺癌瘤株，６１５近交系和津白Ⅱ近交系杂交Ｆ１作为荷瘤动物．按１０种治疗方案进行实验：对照ＤＤＰ、ＣＢＰ、ＡＤＭ、ＣＴＸ、ＣＴＸ＋ＣＢＰ、ＣＴＸ＋ＤＤＰ、ＣＴＸ＋ＡＤＭ、ＣＴＸ＋ＡＤＭ＋ＣＢＰ和ＣＴＸ＋ＡＤＭ＋ＤＤＰ。动物体内试验结果表明：单药的抗瘤活性低，卡铂不如顺铂，三药联合作用明显提高，而ＣＡＣ方案获得与ＣＡＰ方案相似的抗瘤活性。故本实验提示可能用ＣＡＣ方案代替ＣＡＰ方案，使不能接受ＤＤＰ的病人得到与用ＣＡＰ方案相似效果。本实验为临床随机研究提供了科学依据，为乳腺癌治疗提供一个新的有效方案。
In this experiment, mouse transplantable spontaneous breast cancer, 615 inbred and Jinbai II inbred F1 were used as tumor-bearing animals. Experiments were performed on 10 treatment regimes: control DDP, CBP, ADM, CTX, CTX+CBP, CTX+DDP, CTX+ADM, CTX+ADM+CBP, and CTX+ADM+DDP. The results of in vivo animal experiments showed that the single-agent anti-tumor activity was low, carboplatin was inferior to cisplatin, and the combined effect of the three drugs was significantly improved, while the CAC protocol obtained similar anti-tumor activity to the CAP protocol. Therefore, this experiment suggests that the CAC protocol may be used in place of the CAP protocol, so that patients who cannot receive DDP can get similar results with the CAP protocol. This experiment provides scientific basis for clinical randomized studies and provides a new and effective program for breast cancer treatment.